TEAM FENFURO participated in BPCON 2013 – 23rd annual meeting of Indian society for Hypertension held at scientific convention center of King George’s Medical University Lucknow, Uttar Pradesh from 16th to 17th November 2013.
Around 20 international and 20 national faculty of repute came together to bridge the gap of research and clinic and it was attended by approximately 1000 physicians, diabetologist and cardiologists of our country.
1. Society of Toxicology SOT 2014, Phoenix, AZ
March 24, 2014, 9:30 AM to 12:30 PM
CHEMICAL RESOURCES & CEPHAM INC. R&D team presented “Safety, Efficacy and Toxicological Evaluation of a Novel, Patented Anti-Diabetic Extract of Trigonella Foenum-graceum Seed Extract (CR001810)”
The paper and poster generated very favorable response from R&D Teams of Coca-Cola, Pepsico, United States Coast Guard Academy, United States Army Institute of Public Health & United States Food & Drug Administration.
2. KOREA Natural Product Conference, Mokpo, South Korea
April 18, 2014
Invited speaker Dr. Debasis Bagchi, Chief Scientific Officer, Cepham Inc presented a paper titled: “Anti-oxidant and Anti-Diabetic Efficacy of Novel Green Coffee Bean (GCB-70) and TrigonellaFoenum Extracts (FENFURO™)”
The scientific paper and Q&A session followed by the presentation generated a positive response from more than 50 eminent scientists from all over the world present during this session in port city of Mokpo, South Korea.
3. Experimental Biology EB 2014, San Diego, CA
April 29, 2014
CHEMICAL RESOURCES & CEPHAM INC. R&D team presented two abstracts on FENFURO™ and GCB70™ on April 29, 2014.
“Efficacy of a Novel Green Coffee Bean Extract (GCB70™) in Weight Management” & “Anti-Diabetic Efficacy of Fenfuro™, a Novel Trigonella Foenum-Gracium Seed Extract”
4. Vitafoods 2014 Geneva, Switzerland
May 7, 2014 16:10 – 16:35hrs
Chemical Resources & Cepham Inc R&D team led by Dr. Debasis Bagchi presented:
Anti-Diabetic Efficacy of FENFURO™, a Novel Fenugreek Extract
The session was chaired by Prof. Robert Thomas, Addenbrooke’s Hospital, Cambridge University, UK.
TEAM FENFURO participated in 6th World Ayurveda Congress & Arogya held at Pragati Maidan, New Delhi from 06th to 09thNovember 2014.
Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity, PCOS(ploycystic ovarian syndrome) & General Health.
TEAM FENFURO partcipated in Ninth Edition of PHD Chamber’s Annual International Trade Expo “Punjab International Trade Expo (PITEX) 2014 from 4-8 December’2014 at Amritsar, Punjab.The Government of Punjab was the ‘Host State’.
Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity, PCOS(ploycystic ovarian syndrome) & General Health.
Team FENFURO participated in VIBRANT GUJARAT GLOBAL TRADE SHOW – 2015 held at The Exhibition Centre, Near Mahatma Mandir, Gandhinagar, Gujarat during 7th to 13th January, 2015.
Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity & General Health.
Poster Presented on “Clinical evaluation of Standardized Fenugreek seed extract as Furostanolic Saponins (Furocyst) in Polycystic Ovary Syndome Patients at FIGO 2015 Congress at Vancouver, Canada on 4-9 October 2015.
Hon’able Sh.Nitin Gadkari, Union Transport and Highways Minister visited our stall at R&D Sumit, Vigyan Bhawan, New Delhi on dated 07-08 December, 2015
Poster Presentation on “CLINICAL EVALUATION OF FENFURO (FUROSTANOLIC SAPONINS) IN PATIENTS WITH TYPE-2 DIABETES” at 6th World Congress of Diabetes India held on 9thto 12thApril at Hotel ITC Grand Chola Convention Centre Chennai.
Our company has been declared a WINNER in overall evaluation for INDIA SME TOP 100 AWARDS amongst 49023 nominations.
Patients with type 2 diabetes treated with insulin could be exposed to a greater risk of health complications including heart attack, stroke, cancer and eye complications a new study has found.
Examining the UK Clinical Practice Research Datalink (CPRD) – data that characterizes about 10 percent of the UK population – a team of researchers from Cardiff University’s School of Medicine looked at the risk of death for patients taking insulin compared with other treatments designed to lower blood glucose levels in people with type 2 diabetes.
The team’s epidemiological study found people have greater risk of individual complications associated with diabetes such as heart attack, stroke, eye complications and renal disease when compared with patients treated with alternative glucose-lowering treatments.
“Insulin treatment remains the most longstanding blood-glucose-lowering therapies for people with type 2 diabetes, with its use growing markedly in recent years,” according to Professor Craig Currie from Cardiff University’s School of Medicine, who led the study.
“However, with new diabetes therapies and treatments emerging there has been a new spotlight on treatments to ensure what the best and safest form of diabetes treatment is.
“By reviewing data from CPRD between 1999 and 2011 we’ve confirmed there are increased health risks for patients with type 2 diabetes who take insulin to manage their condition,” he adds.
The study adds to previous findings which identified potential health risks of insulin in this specific group of people.
Initial concerns were first raised regarding the use of insulin in type 2 diabetes from a population-based study in Canada, which reported a three-fold increase in mortality.
A similar study of people in UK primary care with type 2 diabetes treated with insulin also reported a 50 percent risk of increased mortality compared with another common treatment regimen.
Professor Currie adds: “Patients currently being treated with insulin should not, under any circumstances, stop taking their medications, and it is important to emphasize that this report related to only type 2 diabetes which typically starts in older people who are overweight.
“Each patient’s individual circumstances are different and treatment decisions are managed by their clinician with all of their medical history fully considered.
“The vast majority of people who take insulin will experience no adverse effects and it remains a reliable and common form of treatment worldwide but this study shows that we need to investigate this matter urgently and the drug regulatory authorities should take interest in this issue.
“Anyone who is concerned should speak to their GP first before taking any action on managing their condition.”
Source: http://jcem.endojournals.org/content/98/2/668.abstract?sid=e5e8ec61-0997-43bd-934b-d4894998abb9
Information on this website has been posted in public interest for creating awareness about general health. In event of any copyright conflicts, please inform so that we may take appropriate remedial measures. The products and the claims made on this site have not been evaluated by FDA and are not approved to diagnose, treat, cure or prevent diseases.
Copyright @ 2021 – All rights reserved Chemical Resources.
